749 Views
Poster Theater Flash Session
Aging and Chronic Disease
Hyojung Kim, MS
Florida International University
Tan Li, Ph.D.
Florida International University
Jacqueline Hernandez, MS, RDN, LD/N
Florida International University
Colby Teeman, MS
Florida International University
Javier Tamargo, PhD student, RDN
Florida International University
Kenneth Sherman, MD, PhD
Gould Professor of Medicine
University of Cincinnati College of Medicine
Susan Rouster, M.S.
University of Cincinnati College of Medicine
Enass Abdel-Hameed, MD, PhD
University of Cincinnati College of Medicine
Juphshy Jasmin, MS
Florida International University
Leslie Seminario, MS
Florida International University
Qingyun Liu, MS
Florida International University
Gustavo Zarini, PhD
Florida International University
Sabrina Martinez, PhD
Florida International University
Joseph Piperato, MD
Project Access, Biscayne Medical
Adriana Campa, PhD, MBD, RD
Florida International University
Marianna Baum, PhD
Florida International University
Objectives :
Antiretroviral therapy has increased life expectancy for HIV infected patients; however, this population is developing chronic illnesses associated with aging. Liver disease is a major cause of non-AIDS mortality, characterized by progressive fibrosis. Infection with HIV and with Hepatitis C Virus (HCV) promotes liver fibrogenesis. Tissue inhibitor of metalloproteinase-1 (TIMP1), inhibits fibrosis regression and is profibrogenic. Association between TIMP1 and liver disease progression in an aging population of HIV/HCV co-infected, HIV mono-infected, HCV mono-infected, and healthy groups from the Miami Adult Studies on HIV (MASH) cohort in Miami, Florida, was investigated.
Methods : Serum TIMP1 levels were determined by ELISA. A non-invasive estimate of liver fibrosis, FIB-4 score was calculated. Liver fibrosis was defined as FIB-4: Low < 1.45, intermediate1.45< =FIB-4< =3.25, High >3.25. ANOVA with Tukey’s test assessed the mean differences of FIB-4 score and TIMP1 level between groups, TIMP1 levels between 3 FIB-4 categories, and the effect of age on FIB-4 and TIMP1. Linear regression predicted the association of FIB-4 score and TIMP-1 level.
Results : Mean age of the cohort was 54.3±8.1 years with no difference between groups. Mean FIB-4 for HIV/HCV co-infected group was the highest among the 4 groups (p< 0.05). Mean TIMP1 for HIV/HCV co-infected group was also the highest among the 4 groups (p< 0.05). FIB-4 and TIMP1 were associated and remained so (β=0.01, SE=0.002, p< 0.001) after adjusting for age. Mean TIMP1 for the high FIB-4 category was the highest among the 3 FIB-4 categories (p< 0.05). There was a direct effect of TIMP1 levels on FIB-4 category (p< 0.001). After adjusting for HIV/HCV co-infection (p< 0.001), HIV infection (p < 0.0001), HCV infection (p< 0.002), non-infection (p< 0.001) and age, the relationship between TIMP1 and FIB-4 remained significant. The adjusted TIMP1 mean for HIV/HCV co-infected group was significantly higher compared to HIV infected (p < 0.0001), HCV infected (p< 0.002), and healthy groups (p < 0.0001), regardless of age.
Conclusions :
Age is a significant factor of liver diseases progression. Our findings of the highest levels of TIMP1 in HIV/HCV co-infected group, which had the highest liver fibrosis regardless of age, supports the role of TIMP1 as a regulator in the progression of hepatic fibrosis.
Funding Sources : National Institutes on Drug Abuse #5UO1DA040381